Omeros | OMER - Cash And Equivalent


Omeros reported $1.9M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Adma Biologics USD 136.02M 2.13M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Cytokinetics USD 255.27M 125.43M Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Immunic USD 186.63M 171.15M Mar/2026
Insmed USD 544.76M 37.42M Jun/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
MacroGenics USD 113.91M 47.39M Jun/2026
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 205.88M 61.57M Jun/2026
Pfizer USD 976M 727M Jun/2026
Rockwell Medical USD 12.48M 1.09M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
United Therapeutics USD 1.8B 523.5M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026